NCT02314143 2019-02-18Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibGlaxoSmithKlinePhase 2 Terminated48 enrolled 20 charts
NCT02538627 2017-09-05Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibMerrimack PharmaceuticalsPhase 1 Terminated5 enrolled
NCT01248858 2017-05-09Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.GlaxoSmithKlinePhase 1 Terminated69 enrolled